NCT04655313Phase 2Completed

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-01-12Actual
Enrollment · participants20Actual
Source updated2023-12-15Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview